{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:32:04Z","timestamp":1770453124081,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bbrc.2019.07.078","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T07:54:34Z","timestamp":1564041274000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A"],"prefix":"10.1016","volume":"517","author":[{"given":"Yunlong","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.07.078_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells, N","volume":"361","author":"Miossec","year":"2009","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.bbrc.2019.07.078_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib7","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.4049\/jimmunol.179.11.7791","article-title":"An IL-17F\/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment","volume":"179","author":"Liang","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib8","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2019.07.078_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/ard.2010.132233","article-title":"IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes","volume":"70","author":"Hot","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2019.07.078_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbrc.2019.07.078_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40265-016-0557-4","article-title":"Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis","volume":"76","author":"Lubrano","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2019.07.078_bib12","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nm.2621","article-title":"Dysregulation of immune homeostasis in autoimmune diseases","volume":"18","author":"Kuchroo","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2019.07.078_bib16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.coi.2011.09.006","article-title":"IL-17 producing cells in host defense and atopy","volume":"23","author":"Milner","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellsig.2010.11.022","article-title":"Signaling of interleukin-17 family cytokines in immunity and inflammation, Cell","volume":"23","author":"Chang","year":"2011","journal-title":"Signal"},{"key":"10.1016\/j.bbrc.2019.07.078_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20110496","article-title":"IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential","volume":"122","author":"Zhu","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.bbrc.2019.07.078_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2005.01.011","article-title":"Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17","volume":"22","author":"Stark","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals","volume":"31","author":"Martin","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.2010.05825.x","article-title":"The IL-17 pathway as a major therapeutic target in autoimmune diseases","volume":"1217","author":"Hu","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2019.07.078_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","article-title":"Burden of disease: psoriasis and psoriatic arthritis","volume":"14","author":"Boehncke","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"issue":"Suppl 2","key":"10.1016\/j.bbrc.2019.07.078_bib25","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2019.07.078_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2019.07.078_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2019.07.078_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2019.07.078_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cyto.2013.03.014","article-title":"The activation and regulation of IL-17 receptor mediated signaling","volume":"62","author":"Song","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrc.2019.07.078_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2019.07.078_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","article-title":"Biologics for the primary care physician: review and treatment of psoriasis","volume":"65","author":"Schadler","year":"2019","journal-title":"Dis. Mon."},{"key":"10.1016\/j.bbrc.2019.07.078_bib32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbrc.2019.07.078_bib34","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.autrev.2018.06.008","article-title":"IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases","volume":"17","author":"Beringer","year":"2018","journal-title":"Autoimmun. Rev."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19314329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19314329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:39:19Z","timestamp":1757763559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X19314329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0006291X19314329"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.078","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}